MAGED2 mediates AKT pathway regulates the biological function of glioblastoma

Glioma is the most common primary intracranial malignant tumor in the brain, and according to the fifth edition of the World Health Organization (WHO) classification, glioblastoma multiforme (GBM) is the most malignant grade IV glioma.The median survival period of GBM patients is only 15 months, and the 5-year survival rate is less than 5%. At present, the treatment of glioma is mainly to achieve maximal safe resectionby surgery by surgery, combined with radiotherapy and chemotherapy, to prolong the patient's survival as much as possible.However, due to the high heterogeneity and invasiveness of glioma, it is easy to relapse after surgery.In addition, the clincal efficacy is not ideal because of the blood-brain barrier and drug resistance. Therefore, it is urgent to find novel targets for glioma treatment. MAGE-D2 (MAGE Family Member D2) is a member of the melanoma-associated antigen type II subfamily. MAGE-D2 has been identified as being critical for transcriptional regulation, epigenetic alteration, cell development and differentiation,and is involved in the regulation of cell cycle. Furthermore, numerous studies have shown that MAGE-D2 is a tumor-specific antigen that plays an important role in tumor progression and metastasis, including hepatocellular carcinoma, gastric cancer, and lymphoma. However, the precise function and mechanism of MAGE-D2 in glioma is still unknown.